Physician profile
Thu P Ho
NPI 1245437433
$5,412.18
in general payments reported to CMS, 2019-2025
31 companies · $1,146 in 2025
The $1,146 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $243 · 2020: $327 · 2021: $699 · 2022: $904 · 2023: $1,182 · 2024: $912 · 2025: $1,146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,239.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $681.38 | 2019-2025 | Benlysta |
| Novo Nordisk INC | $552.52 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $536.53 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Ibsa Pharma INC. | $527.58 | 2019-2024 | Tirosint, Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $472.21 | 2019-2025 | |
| Amgen INC. | $378.97 | 2019-2024 | Enbrel, Otezla, Tavneos |
| Lilly USA, LLC | $341.39 | 2019-2025 | Baqsimi, Lyumjev, Jardiance |
| Astrazeneca Pharmaceuticals LP | $217.40 | 2021-2024 | Saphnelo |
| Abbvie INC. | $195.19 | 2019-2025 | |
| Abbott Laboratories | $182.77 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Mannkind Corporation | $181.83 | 2021-2024 | Afrezza |
| Pfizer INC. | $147.54 | 2022-2025 | |
| Horizon Therapeutics Plc | $139.58 | 2023 | Tepezza, Krystexxa |
| Alexion Pharmaceuticals, INC. | $110.55 | 2019-2025 | Strensiq |
| Dexcom, INC. | $109.28 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascensia Diabetes Care US INC. | $93.83 | 2024 | |
| Tandem Diabetes Care, INC. | $86.04 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Tolmar Pharmaceuticals, INC. | $81.17 | 2021-2022 | |
| Recordati_rare_diseases_inc. | $65.66 | 2023-2024 | Isturisa, Signifor Lar |
| Companion Medical, INC. | $35.93 | 2019-2020 | |
| Insulet Corporation | $32.73 | 2019 | |
| Ucb, INC. | $32.05 | 2022 | |
| Merck Sharp & Dohme LLC | $31.52 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $26.84 | 2024 | Lupkynis |
| Almatica Pharma LLC | $26.32 | 2024 | Teriparatide |
| Esperion Therapeutics, INC. | $24.02 | 2024 | Nexletol |
| Neurocrine Biosciences, INC. | $23.88 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.67 | 2021 | |
| Janssen Biotech, INC. | $22.56 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $17.80 | 2021 | |
| Amryt Pharma Holdings LTD | $13.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thu Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.